Related Experiment Videos
Properties of a selective kappa agonist, U-50,488H
Life Sciences
|November 15, 1982
Summary
U-50,488H acts as an analgesic in rodents, but requires higher naloxone doses than morphine. This compound selectively targets opioid kappa receptors, showing tolerance with chronic use but not physical dependence.
Area of Science:
- Pharmacology
- Neuroscience
- Receptor Binding Assays
Background:
- U-50,488H exhibits naloxone-antagonizable analgesic effects in rodents.
- Its analgesic dose of naloxone is higher compared to morphine.
- Chronic administration leads to tolerance but not physical dependence.
Purpose of the Study:
- To investigate the receptor binding profile of U-50,488H.
- To determine the selectivity of U-50,488H for opioid receptor subtypes.
- To understand the pharmacological properties of U-50,488H in relation to known opioids.
Main Methods:
- Rodent models for analgesic and dependence studies.
- Drug discrimination assays in trained monkeys.
- In vitro receptor binding assays using radioligands (3H-EKC).
Main Results:
- U-50,488H demonstrated cross-tolerance with bremazocine, but not morphine.
- Monkeys generalized U-50,488H to ethylketocyclazocine (EKC) discrimination.
- Binding assays revealed high affinity for kappa receptors (Ki = 114 nM) and low affinity for mu receptors (Ki = 6100 nM).
Conclusions:
- U-50,488H functions as a selective agonist at the opioid kappa receptor.
- The compound's pharmacological profile differs significantly from morphine.
- Findings support the role of kappa receptors in mediating the effects of U-50,488H.